Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Inclusion Criteria

• •Disease Characteristics:
• •Patients with a documented histologic or cytologic diagnosis of a colonic or rectal malignancy.
• •Age Range: Male or Female at least 18 years of age
• •Performance Status: Patients with a Karnofsky performance status \> 70% (or equivalent, ECOG 0-1) and expected survival of at least 3 months.
• •Hematopoietic: Hemoglobin \> 10 g/dL; WBC \> 3000 per mm3; Granulocyte count \> 1,500 per mm3; Platelet count \> 100,000 per mm3
• •Hepatic: Total bilirubin \< 1.5 times the institutional upper limit of normal (IULN)AST or ALT \< 2 x IULN
• •Renal: Creatinine \< IULN
• •Cardiovascular: Patients with LVEF \>/= 50% by required MUGA/2D-ECHO study.
• •Pulmonary: Patients with DFCO and FEV1 \>/= 60% by required Pulmonary Function Tests.
• •Other: Patients who have had a prior imaging study with a murine monoclonal antibody may be included. Patients agreeing to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent.